Delpharm has proclaimed its agreement with Inventiva to manufacture lanifibranor, a drug candidate entering a pivotal third Phase clinical trial in non-alcoholic steatohepatitis (NASH) at its manufacturing plant in Reims. The company produced the first clinical batches in Q2 2021 and will supply consignments for phase 3.
The Delpharm development unit based in Reims is specialized in oral solid dosage form and is committed to providing flexibility and high-quality services for batch sizes ranging from 50g to 1000kg to cover all clinical needs. “Delpharm Development is proud to take an active role in Inventiva endeavor to help patients suffering from NASH to access this promising new treatment rapidly,” said Jean Bernard Dumas, Chief Scientific Officer at Delpharm.
“Inventiva is reaching a pivotal milestone with the initiation of its Phase III, and we are thrilled to have an experienced partner like Delpharm to ensure the production of several millions of tablets of lanifibranor to supply our clinical trial sites worldwide,” stated Frederic Cren, CEO of Inventiva.
